Abiopharma

🔍 Bell Michael Brian (Executive)

Company: Guardant Health, Inc. (GH)

Report Date: 2025-12-05

Detailed Transactions and Holdings:

• Acquired 29,382 shares of Common Stock at $32.86 per share (Direct)
  Date: 2025-12-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 81,509.00 | transaction_form_type: 4
• Acquired 26,905 shares of Common Stock at $28.37 per share (Direct)
  Date: 2025-12-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 108,414.00 | transaction_form_type: 4
• Sold 8,033 shares of Common Stock at $101.4236 per share (Direct)
  Date: 2025-12-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 100,381.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 22,891 shares of Common Stock at $102.1057 per share (Direct)
  Date: 2025-12-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 77,490.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 7,567 shares of Common Stock at $103.2634 per share (Direct)
  Date: 2025-12-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 69,923.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 11,978 shares of Common Stock at $103.9616 per share (Direct)
  Date: 2025-12-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 57,945.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 250 shares of Common Stock at $105.816 per share (Direct)
  Date: 2025-12-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 57,695.00 | transaction_form_type: 4 | Footnotes: F5
• Sold 5,568 shares of Common Stock at $106.6843 per share (Direct)
  Date: 2025-12-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 52,127.00 | transaction_form_type: 4 | Footnotes: F6
• Sold 3,267 shares of Common Stock at $101.464 per share (Direct)
  Date: 2025-12-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 48,860.00 | transaction_form_type: 4 | Footnotes: F7
• Sold 8,774 shares of Common Stock at $102.1121 per share (Direct)
  Date: 2025-12-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 40,086.00 | transaction_form_type: 4 | Footnotes: F8
• Sold 2,533 shares of Common Stock at $103.2409 per share (Direct)
  Date: 2025-12-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 37,553.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 5,027 shares of Common Stock at $103.9609 per share (Direct)
  Date: 2025-12-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 32,526.00 | transaction_form_type: 4 | Footnotes: F9
• Sold 3,284 shares of Common Stock at $106.7017 per share (Direct)
  Date: 2025-12-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 29,242.00 | transaction_form_type: 4 | Footnotes: F10
• Sold 1,190 shares of Common Stock at $107.2625 per share (Direct)
  Date: 2025-12-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 28,052.00 | transaction_form_type: 4 | Footnotes: F11
• Sold 29,382 shares of Stock Option (Right to Buy) at $32.86 per share (Derivative)
  Date: 2025-12-05 | Code: M | Expires: 2033-06-09 | equity_swap_involved: 0 | shares_owned_after: 7,137.00 | transaction_form_type: 4 | Footnotes: F12
• Sold 26,905 shares of Stock Option (Right to Buy) at $28.37 per share (Derivative)
  Date: 2025-12-05 | Code: M | Expires: 2033-12-13 | equity_swap_involved: 0 | shares_owned_after: 10,421.00 | transaction_form_type: 4 | Footnotes: F13

Footnotes:

• F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.715 to $101.705. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
• F2: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.715 to $102.690. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
• F3: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.720 to $103.710. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
• F4: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $103.720 to $104.440. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
• F5: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.415 to $106.390. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
• F6: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.420 to $106.980. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
• F7: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.710 to $101.700. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
• F8: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.715 to $102.670. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
• F9: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $103.720 to $104.510. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
• F10: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.935 to $106.925. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
• F11: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.010 to $107.390. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
• F12: The stock option vests as to 33% of the shares subject to such award on June 9, 2024, and as to the remaining 67% of the shares subject to such award in substantially equity installments on each monthly anniversary of June 9, 2024, during the two-year period thereafter.
• F13: This represents a stock option granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.